Podcasts about microrna

Dive into the science behind the power of breastmilk and how it applies clinically.Guest: Dr. Richard Noel, MD, PhDEarn 0.10 ASHA CEUs for this episode with Speech Therapy PDWatch on YoutubeMichelle and Richard lean into the “nerdy details” behind early nutrition and why it matters so much for the infants we serve. Their conversation walks through clinical guidance on probiotics in the NICU, unpacks the emerging science of microRNA, and connects these concepts to real-world infant growth, gut health, and feeding outcomes. Michelle helps you translate the science into what it means at the bedside, in early intervention, and in caregiver conversations. If you've ever wanted a clearer, evidence-based understanding of why breastmilk exposure supports GI development and how to talk about it with families, this episode delivers.About the Guest: Dr. Richard Noel, MD, PhD, Division Chief for Pediatric GI at Baylor College of Medicine at CHRISTUS Children's Hospital in San Antonio and volunteer Medical Director for Feeding Matters.Show Notes:Healthy Children's Lactation ProjectIBCLCGold LactationFeeding Matters

Description: "When joint pain is present, the diagnosis of psoriatic arthritis needs to be made as soon as possible, ideally within six months to limit joint inflammation" Dr. Vinod Chandran mentions as he discusses efforts to identify a diagnostic test for those at risk of developing psoriatic arthritis.          Join host Jeff Brown as he speaks with leading rheumatologist and clinician scientist Dr. Vinod Chandran, Director of the Gladman Krembil Psoriatic Arthritis Program, Schroeder Arthritis Institute, University Health Network and the Departments of Medicine, Laboratory Medicine and Pathobiology, and the Institute of Medical Science at the University of Toronto to learn more about the progress and promising results towards developing a psoriatic arthritis diagnostic test through multi-omic assays and identifying the distinct differences between psoriasis and psoriatic arthritis.  This episode provides an update on the progress to date of the NPF PsA Diagnostic Test grant initiative which has shown promising results with a potential test entering prospective study in multiple sites soon.   Thank you to Johnson and Johnson for their support of this program activity. Timestamps: (0:00)          Intro to Psoriasis Uncovered & guest welcome rheumatologist Dr. Vinod Chandran.    (0:52)          It is challenging to diagnose psoriatic arthritis with many factors leading to a delay in diagnosis. (4:56)          The start of Dr. Chandran's involvement with the PsA Diagnostic Test Grant project.   (7:55)          The different types of omics and the definition of multi-omic. (9:57)          How the multi-omic approach is used to find biomarkers relative to a specific disease pattern. (11:08)        Development of a predictive or prevention-based test using gene expression.      (13:46)        First year results identify 200 markers across different omic approaches that distinguish psoriatic arthritis from psoriasis.    (14:58)        The significance of MRNA vs mIcroRNA's use in development of a diagnostic test and how critical that is to dissemination of a                     potential test. (17:08)        Identifying the skin-joint axis in relation to different types of arthritis. (20:20)        Next steps to moving the diagnostic test research forward as a prospective study in multiple sites and the cost effectiveness of                  delivering the test.   (23:13)        If you have psoriasis, musculoskeletal, back, and joint pain think of psoriatic arthritis and be diagnosed early to maintain a good                 quality of life. Key Takeaways: ·       Given challenges associated with diagnosing psoriatic arthritis and the impact on quality of life, in 2019 NPF launched the PsA Diagnostic Test Grant project with the goal of developing an early stage test that would identify and diagnose those with psoriatic arthritis before debilitating  joint damage begins.   ·       Progress towards a PsA Diagnostic Test includes the study of multi-omic data sets where 200 distinct biomarkers have been identified leading to a greater understanding of the different pathways between psoriatic arthritis, psoriasis, and the skin joint axis.  ·       A potential diagnostic test is now moving towards the prospective study phase. Until the test is available and if joint pain is present and you have psoriasis, ask your health care provider if it could be psoriatic arthritis and treat appropriately.  Guest Bio: Vinod Chandran, MBBS, MD, DM, PhD is a rheumatologist, clinician scientist, and Director of the Gladman Krembil Psoriatic Arthritis Program, Schroeder Arthritis Institute, University Health Network and the Departments of Medicine, Laboratory Medicine and Pathobiology, and the Institute of Medical Science at the University of Toronto where he is also a Professor of Medicine. His specialties include internal medicine, immunology, rheumatology, and genetic epidemiology. His research focus is on the development of biomarker-based strategies to improve early diagnosis and prognosis of psoriasis and psoriatic arthritis, identification of new treatment targets especially for those who do not respond to current therapies, and strategies to reduce the impact of disease. Dr. Chandran is a Co-Vice President of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis or GRAPPA. He is an active collaborator in a multi-center research consortia such as the International Psoriasis and Arthritis Research Team and the Spondyloarthritis Research Consortium of Canada. Dr. Chandran is the recipient of research funding from the National Psoriasis Foundation for his work in identifying a "Multi-omic Diagnostic Test for PsA in Psoriasis Patients". Resources: "Understanding the NPF Psoriatic Arthritis Diagnostic Test Grant Outcomes" Advance Online. February 18, 2026.  "Managing Chronic Pain with Psoriatic Arthritis" Psoriasis Uncovered podcast episode with physiatrist Dr. Erin Maslowski, LB Herbert who lives with psoriatic disease, and moderator Susan McClelland-Tobert, a retired pediatric cardiologist who also lives with psoriatic disease. Glossary of terms: mRNA: Messenger RNA carries protein information or instructions from the DNA in a cell's nucleus to the cell's interior where the sequence is read and translated into corresponding amino acids for growing protein chains. Micro-RNA (miRNA):  Micro-RNA act as the regulator. They are short and bind to specific target mRNA's to degrade or inhibit production of protein. 

Hosts: Ed Jones (Owner – Nutrition World) & Clint Powell A variety of topics all related to living a healthy lifestyle Presented by: Nutrition World www.nutritionw.com Broadcasting from the Nooga Dentistry Studio www.noogadentistry.com Production of: Whitfield Media Group www.vitalhealthradio.com Show Summary & Time Stamps: Title: Peak Span Living: A2 Milk, Oxalates, and AI-Optimized Health [0:00:00] Intro, and Today's Agenda Ed previews today's focus: A1 vs. A2 milk Ed's “Where did Ed eat this week in Chattanooga?” food rundown. [0:02:43] “Where Did Ed Eat?” – Restaurant Choices & Macro Strategy Ed's restaurant decision “trifecta”: Macros & food quality (close to the earth, protein and fats quality). Type of fat (prefers healthy fats; brings his own olive oil). Carbs ≤ 60 grams per meal when possible. Stops & comments: Maple Street Biscuit Company – Impressed overall; chooses a bowl (eggs, bacon, avocado, tomato, feta) instead of biscuits to keep carbs lower. Doc Holiday (Hixson) – Tallow-cooked foods, excellent broccoli, “biker bar” vibe but friendly. Miller's Ale House – Fresh salad with olive oil only; hamburger steak (no gravy) with mushrooms/onions; occasional baked potato post–workout for carbs. Acropolis – Long-time favorite; good quality foods. Only criticism: no real butter for steak (avoids margarine). Portofino – Typically orders shish kebabs (high protein, low carb), with broccoli and salad; brings own olive oil.  Harry's at Hamilton Place – Custom “Lexatonian” salad, light dressing, double ground beef = high protein, moderate carbs, low fat (adds olive oil). Transition: Ed mentions hiring PR expert Amy Summers (NYC) to push Nutrition World and The Holistic Navigator onto national TV. [0:08:36] New Ebooks & Key Health Themes Ed outlines his growing ebook library (free at theholisticnavigator.com/resources): Sleep: Strategies for improving restorative sleep. “Are You Sick and Tired of Being Sick and Tired?”  Food choices Nutrients Ed's personal ~68 pills/day longevity stack (not a recommendation, but max-longevity model). Immune System: Maintenance + what to do “when under the weather.” Oxalates:How certain “healthy” foods (oxalates) can destroy joints and drive pain. Core Four: If you only take four supplements, which foundational ones matter most from Ed's 47 years of observation. (Coming) Using AI to massively optimize health & fitness – Ed uses AI multiple times a day to optimize training, eating, supplements, and protein for his upcoming Chattanooga Fitness bodybuilding contest (11 weeks out). Quick side notes: Iodine nasal spray – New formulation he and Clint like: less burn, better value, used 2–3x/day. Reminder about Best of the Best local voting, including Nutrition World and podcast nominations. [0:15:38] Fruits/Veg & Lung Cancer Article, Glyphosate, and “Health Halo” Effect Topic: Article headline – more fruits and vegetables linked to higher lung cancer risk (under age 50). Ed's three-part interpretation: Glyphosate (Roundup) exposure: More produce = more glyphosate, unless it's clean. References Dr. Zach Bush's work on glyphosate and chronic disease. Suggests Fire Hawk herbicide (sold at Nutrition World) as a glyphosate-free yard option (dehydrates plants rather than poisoning). Fear as a toxin – Long-term fear can crush health, even when intentions are to “eat healthy.” Health halo compensation effect: Study reviewed by Dr. Greger (nutritionfacts.org): Adding healthy foods to fast-food menus led people to eat more unhealthy items: “If I eat the salad/broccoli, I can have double fries + dessert.” Psychological “armor” effect from one healthy choice leading to more indulgence. [0:19:38] Supplements, Safety Fears, Herbs & Tryptophan Case Discussion of fear-driven headlines around herbs and liver toxicity: Example: a Chinese herb flagged for liver issues; deeper read shows cases involved people also on multiple drugs. Comfrey is the one herb Ed agrees shouldn't have been sold widely due to genuine liver toxicity (Nutrition World doesn't sell it). Tryptophan contamination incident (25–30 years ago): One bad overseas batch contaminated in production (likely bacterial issue). Resulted in deaths, but: Problem was manufacturing contamination, not tryptophan itself. Takeaway: Quality and clean manufacturing are crucial. Long-standing, widely used herbs/supplements would have more robust safety signals by now if they were truly dangerous. [0:21:41] Toilet Paper Chemicals & “Real” Brand Recommendation Ed cites testing from Mamavation on toxic chemicals in toilet paper: Concern: endocrine-disrupting chemicals (EDCs) that can be absorbed through sensitive, moist tissue. Ed's preferred brand at Nutrition World: Reel: 3-ply, No inks, dyes, BPA and made from bamboo. “Lower-chemical” grocery-store options from the Mamavation testing: Angel Soft 230+ Cottonelle Mega Ultra Kirkland Bath Tissue (Costco) Trader Joe's toilet paper Quilted Northern Ultra Plush Clint's push: Rather than memorize brands and chemistry, just shop where you trust the vetting (e.g., Nutrition World). [0:25:03] A1 vs. A2 Milk, Lactose Intolerance & Ancient Nutrition A2 Study discussed (Chinese adults, n=600): Compared: Conventional milk (contains A1 beta-casein) vs A2-only milk (contains A2 beta-casein). Key findings: Reduced GI symptoms (bloating, abdominal pain, etc.) with A2 milk. Benefits observed across different age groups, both lactose absorbers and malabsorbers. Implications: Many who believe they're lactose intolerant may actually be reacting to A1 casein, not lactose. A2 milk/protein could allow some to tolerate dairy better. Practical angle: Ed personally drinks Ancient Nutrition A2 protein and tolerates it very well. Clint notes some standard protein drinks upset his digestion. [0:27:11] Autism, EMFs, and Mitigation Tools Framing: Autism as a systems issue, not a single-disease point. Cites Dr. Martha Herbert's perspective: Autism may develop from environmental irritants that excite the brain: Toxins (e.g., mercury, glyphosate) Allergens EMFs (electromagnetic fields) Vaccine adjuvants/excipients, etc. EMFs & mitigation: Ed acknowledges we can't avoid EMFs (phones, Wi-Fi, 5G), but we can reduce exposure. Tools Ed uses: SafeSleeve phone case: Claims ~90% EMF reduction; Ed's own measurements suggest ~60%. Effective when phone is close to the body. Blue Shield EMF devices: Plugs in, emits “healthy EMF” fields that may reduce impact of other EMFs. Ed uses a ~$500 model in his bedroom. Mentions BlueShield.com, discount code “nutworld”. [0:30:40] Paternal Exercise & Offspring Fitness (MicroRNA Study) Citing work discussed by Peter Attia: Paternal exercise before conception can improve offspring endurance capacity. Mechanism: changes in sperm microRNA profiles. Mouse model: Transferring RNA from fit to unfit mice improved fitness traits in offspring. Ed's takeaway: Yet another compelling reason for men to exercise before having children. Wonders if his own daughter benefited from his lifelong fitness. [0:35:37] Peak Span, Aging, Sleep, Mouth Tape & Oxalate Pain Ed defines “Peak Span” as: The period of life where we maintain near-optimal health, vitality, and energy (like our 20s). Notes U.S. spends $5.1 trillion on healthcare (18% of GDP) yet ranks 35/36 among high-income countries in outcomes. Mistakes shortening peak span: Poor diet (inflammatory foods, bad fats, high carbs). Confusion around what “healthy eating” means. Underestimating small daily habits. Sleep: 25% of Americans have diagnosable insomnia, ~50% have occasional insomnia 1st big issue: loss of sleep rhythm: Irregular bedtimes fragment circadian patterns. Recommends going to bed within 1 hour of the same time most nights. Single high-impact change: stop mouth breathing at night. Ed has used mouth tape for ~25 years. Benefits: less anxiety, better restorative sleep (cites James Nestor's “Breath”). Uses an Oura Ring and sees notable improvements with mouth taping. Pain & Oxalates: Ed's history: 25 years of rotating pains; then severe hip pain leading to bilateral hip replacement. Suspects long-term high oxalate diet as a major contributor. High-oxalate foods he over-consumed: Spinach Beets Almonds & almond butter Raspberries and other known high-oxalate foods. Source: Sally Norton's “Toxic Superfoods”. Elimination approach: No perfect test; best method is removing high-oxalate foods and observing. Often, pain temporarily worsens in 2–4 weeks as oxalates mobilize, then improves. Result: Now, near age 69, Ed reports zero pain after hip replacements + oxalate restriction. [0:44:14] Using AI as a Health & Fitness Coach Ed uses AI (specifically ChatGPT) as a: Training coach for his bodybuilding prep (11 weeks out). Nutrition advisor and accountability partner. Inputs: Goals and timeline. Age, weight, health status. Photos of himself. Photos of every meal (taken at a 45° angle). AI provides: Calorie and macro estimates (calories often “spot on”). Advice: “Too much / too little,” adjust protein/fat/carbs. Day-to-day training and nutrition refinements. Role vs. human coaching: Doesn't replace human experts; can complement them. Ed still believes in a “team” approach (quality practitioners + AI). [0:46:00] Where to Find Ed's Content & Resources Ed's main platforms: TikTok: “Nutrition World Tennessee” – many short-form health and performance clips (especially athletics). Website: nutritionw.com – hub for: Store Articles, videos, education. The Holistic Navigator (theholisticnavigator.com): Home for his ebooks (sleep, immune, oxalates, core four, AI & health, etc.). Long-form educational content. Podcasts / Radio: Vital Health Radio – full archive at vitalhealthradio.com and all major podcast apps. Other shows hosted or shared via noogapodcasts.com (Clint's platform). [0:52:21] Melatonin, Sleep, Cold Therapy, and Upcoming Peptide Episode Melatonin: Notes that ~99% of melatonin on the market is synthetic. Issues some people experience with synthetic forms: Vivid dreams & Inconsistent sleep quality. Recommends Symphony brand: Plant-derived melatonin, not synthesized. Immune aspects: Mentions integrative cancer doctors using high-dose melatonin in protocols. References Dr. Michael Smith discussing high-dose melatonin in COVID on The Holistic Navigator. Cold therapy & gout: Dr. Greger review: cold-water immersion for gout: 20 minutes/day in cold water for a few weeks: ↓ pain, stress, anxiety, depression. ↑ joint mobility, activity, quality of life. For general muscle pain, cold immersion: Only helps during immersion; no lasting benefit. Heat is more beneficial for ongoing muscle pain after the acute phase. Exception: first ~24 hours post-injury when cold can curb acute inflammation (classic RICE). Peptides & future content: Mentions RFK Jr. and the possibility of peptide injections reaching shelves with regulatory shifts. The post Radio Show / Podcast – April 26, 2026 first appeared on Vital Health Radio.

In this episode of It Takes Balls, Dr. Sia Daneshmand, a leading urologic oncologist at USC, joins the conversation to break down the realities of testicular cancer treatment, surgery, and long-term outcomes. Known for his expertise in complex cases and extraperitoneal RPLNDs, Dr. Daneshmand shares how advances in surgery and a personalized approach to care are improving survival while reducing unnecessary treatment.The discussion dives into critical decisions patients face after diagnosis, including when surveillance vs. treatment is appropriate and how factors like tumor type, staging, and risk influence the path forward. Dr. Daneshmand explains the role of retroperitoneal lymph node dissection (RPLND), when it's necessary, and how surgical expertise can dramatically impact outcomes and quality of life.Beyond treatment, this episode explores the importance of being treated at high-volume centers, avoiding overtreatment, and understanding the long-term effects of both surgery and chemotherapy. Dr. Daneshmand also discusses the status and future of MicroRNA 371 biomarker testing.Whether you're newly diagnosed, considering surgery, or learning more about testicular cancer treatment options, this episode provides trusted insight from one of the leading experts in the field helping patients make informed decisions with confidence.Provide your feedback on the podcast:https://www.testicularcancerawarenessfoundation.org/itbsurveyHave a question for a future expert guest? Submit here:https://www.testicularcancerawarenessfoundation.org/it-takes-balls-question-submissionWant to be a guest? Apply here:https://www.testicularcancerawarenessfoundation.org/it-takes-balls-submissionsFollow Testicular Cancer Awareness Foundation:⁠https://www.testescancer.orghttps://www.twitter.com/testescancer⁠⁠https://www.instagram.com/testescancerhttps://www.facebook.com/tca.orgDr. Daneshmand:https://keck.usc.edu/faculty-search/siamak-daneshmand/https://www.linkedin.com/in/sia-daneshmand-m-d-569166b/https://x.com/siadaneshmandFollow Steven Crocker:https://www.twitter.com/stevencrockerhttps://www.instagram.com/stevencrockerhttps://www.facebook.com/steven.crocker2Theme song: No Time Like Now - Tom Willner www.tomwillner.com

This podcast features Dr. Mike Glover from MDACC discussing recent advances in germ cell tumor research, focusing on novel biomarkers like microRNA and ctDNA, and emerging therapies targeting Claudin-6. The conversation explores how these innovations could transform diagnosis, prognosis, and treatment strategies.

Send a textA splenic mass is one of those findings that can flip a normal day into a crisis. You may have an older Labrador or Golden Retriever, an ultrasound that shows a splenic tumor, and an owner asking the question you cannot fully answer yet: “Is it cancer?” We sit down with Dr. Janet Grimes to unpack why that gap between suspicion and certainty is so hard in canine medicine and why better preoperative diagnostics for splenic masses could change everything from emergency decisions to long-term screening.We walk through what veterinarians currently juggle when counseling clients, including the role of hemoabdomen, the wide spread in prognosis between benign lesions and canine hemangiosarcoma, and how rules of thumb like the double two-thirds rule fit (or do not fit) in different clinical scenarios. Then we zoom in on the science of microRNAs: tiny non-coding RNA molecules that regulate gene expression and can be detected in circulation, making them promising minimally invasive biomarkers for veterinary oncology.Dr. Grimes explains how a multi-marker microRNA panel is built from blood samples and measured with quantitative RT-PCR, why panels can be more specific than single markers, and what it could look like to use this as a send-out test today with the longer-term goal of a cage-side diagnostic. We also discuss the real-world barriers: differentiating hemangiosarcoma from other splenic malignancies, avoiding misleading results in sick dogs, and integrating any new test as an adjunct to physical exam, imaging, and standard lab work.If you care about earlier cancer detection in dogs, smarter decision-making around splenectomy, and the future of blood-based cancer diagnostics, listen through to the end and share this with a colleague. Subscribe, leave a rating and review, and tell us what question you most want a pre-op splenic mass test to answer.AJVR articles: https://doi.org/10.2460/ajvr.25.07.0258 and https://doi.org/10.2460/ajvr.25.07.0250INTERESTED IN SUBMITTING YOUR MANUSCRIPT TO JAVMA ®  OR AJVR ® ?JAVMA ® : https://avma.org/JAVMAAuthorsAJVR ® : https://avma.org/AJVRAuthorsFOLLOW US:JAVMA ® :Facebook: Journal of the American Veterinary Medical Association - JAVMA | FacebookInstagram: JAVMA (@avma_javma) • Instagram photos and videosTwitter: JAVMA (@AVMAJAVMA) / Twitter AJVR ® : Facebook: American Journal of Veterinary Research - AJVR | FacebookInstagram: AJVR (@ajvroa) • Instagram photos and videosTwitter: AJVR (@AJVROA) / TwitterJAVMA ®  and AJVR ®  LinkedIn: https://linkedin.com/company/avma-journals

Fatty liver disease is the most common liver disorder, driven by obesity, Type 2 diabetes, and insulin resistance. It often progresses silently for years before symptoms appear Niacin helps your body use energy better. It turns down a molecule called microRNA-93, which normally blocks two key proteins that help your cells make energy and burn fat. By restoring those proteins, niacin helps your mitochondria work more efficiently. This shift supports fat burning in your liver instead of fat storage Higher niacin intake has been linked to reduced liver fat, lower inflammation, improved insulin sensitivity, better cholesterol levels, and reduced long-term mortality in fatty liver patients Niacinamide is the better choice compared to niacin because of its function as an NAD+ precursor. The ideal dosage is 50 milligrams three times a day, ideally in powder form for precise intake. Niacinamide also doesn't cause skin flushing Increasing choline intake is the best way to manage fatty liver disease. Research shows it helps transport fat out of the liver. While there are several types of choline supplements available, citicoline is the preferred one because of its high bioavailability

Send a textGene regulation through RNAs, the neurobiology of opioid addiction, and how psychedelics affect drug-seeking by modulating inflammation and plasticity. Not medical advice.TOPICS DISCUSSED:Gene regulation basics: DNA transcribes to RNAs, including non-coding types like microRNAs that inhibit mRNA translation into proteins, influencing up to 60% of the proteome.Non-coding RNAs in neuroplasticity: MicroRNAs and circular RNAs regulate synaptic changes, with activity-induced ones like miR-485-5p linked to rapid responses in drug cue memory and addiction reinforcement.Opioid addiction models: Rats self-administer heroin or fentanyl via levers, showing compulsive seeking; fentanyl's higher potency drives faster learning but similar long-term effects to heroin when doses are equated.Differences between opioids: Heroin and fentanyl both activate mu-opioid receptors for euphoria and dopamine release, but fentanyl lingers longer; no major behavioral differences in seeking once potency is matched.Psilocybin's effects on addiction: A single psilocybin dose post-abstinence reduces heroin-seeking in rats by dampening neuroinflammation in brain regions like the nucleus accumbens and prefrontal cortex.Brain Inflammation: Opioids induce pro-inflammatory changes via cytokines like IL-17A and pathways like TNF-alpha, leading to glial activation and blood-brain barrier leaks; psilocybin counters this.MicroRNA biomarkers: Blood microRNAs reflect gene expression patterns tied to disease states, with potential to predict opioid relapse risk, treatment response, or neonatal withdrawal severity non-invasively.Future research: Ongoing work links psilocybin's serotonin 2A activation to anti-inflammatory gene changes, plus human studies on microRNAs for personalized addiction treatments.ABOUT THE GUEST: Stephanie Daws, PhD is an associate professor at Temple University in the Center for Substance Abuse Research and Department of Neurosciences, where she researches mechanisms of drug-seeking behavior with a focus on opioids and psychedelics.RELATED EPISODE:M&M 2 | Psilocybin, LSD, Ketamine, InflamSupport the showHealth Products by M&M Partners: SporesMD: Premium mushrooms products (gourmet mushrooms, nootropics, research). Use code 'nickjikomes' for 20% off. Lumen device: Optimize your metabolism for weight loss or athletic performance. MINDMATTER gets you 15% off. AquaTru: Water filtration devices that remove microplastics, metals, bacteria, and more from your drinking water. Through link, $100 off AquaTru Carafe, Classic & Under Sink Units; $300 off Freestanding models. Seed Oil Scout: Find restaurants with seed oil-free options, scan food products to see what they're hiding, with this easy-to-use mobile app. KetoCitra—Ketone body BHB + electrolytes formulated for kidney health. Use code MIND20 for 20% off any subscription (cancel anytime) For all the ways you can support my efforts

A promising new experimental medication for PKD is generating a lot of excitement — and for good reason. In this research review episode, Diana breaks down what Farabursen is, how it works at the genetic level, and why targeting microRNA may help increase polycystin protein production and potentially halt cyst growth. If you want a science-backed look at where PKD treatment may be headed — this episode is for you! You'll learn a simple explanation of DNA, genes, and protein signaling, what early studies are showing so far, what phase 3 trials may look like, and who may qualify to participate. RESOURCES & LINKS Show notes, references, and transcript: https://www.thepkddietitian.com/54 Farabursen Blog: https://www.thepkddietitian.com/blog/farabursen-what-is-it-and-how-does-it-impact-pkd-progression DISCLAIMER: The PKD Dietitian Podcast is for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Broadcast from KSQD, Santa Cruz on 1-01-2025: An emailer asks about omega-3 supplementation for memory at age 72. Dr. Dawn advises checking that fish oil capsules contain adequate DHA—at least 1,000 mg—since many omega-3 products have low DHA levels. She notes Medicare covers the same testing at standard labs as proprietary labs like OmegaQuant that charge patients directly. Beyond omega-3s, she emphasizes glucose control (hemoglobin A1c below 5.6) since the enzyme that breaks down insulin also clears beta-amyloid, and weight training to raise brain-derived neurotrophic factor (BDNF), which promotes new synapse formation essential for memory. Dr. Dawn reviews Popular Science's top 2025 health innovation: eye drops from Lens Therapeutics containing aceclidine that correct age-related farsightedness for 10 hours. The drops shrink the pupil to increase depth of field, improving near vision by three or more lines on eye charts within 30 minutes without affecting distance vision. Side effects include eye irritation, dimmed night vision, and headache. She describes Duke University's breakthrough allowing heart transplants from circulatory death donors using an on-table reanimation technique. This could expand the pediatric donor pool by 20%—critical since up to 20% of children die waiting for transplants. Dr. Dawn celebrates CAR-T immunotherapy for multiple myeloma, which saved her husband's life. Of 97 heavily pretreated patients, 38% achieved complete remission still present at five years, with over 50% total survival. The therapy removes T-cells, uses CRISPR to add receptors targeting cancer cell antigens, then reinfuses the modified cells. She highlights a UC Davis study showing remote blood pressure monitoring with home technology, education, and coaching dropped patients' average blood pressure from 150/80 to 125/74 in months—low-tech with high impact. Dr. Dawn explains the Nano Knife for prostate cancer, which uses localized electrical pulses delivered through thin wires to destroy tumors while sparing surrounding nerves. This minimally invasive approach could reduce erectile dysfunction and incontinence common with traditional surgery. She describes Gilead's Sunlenca, a twice-yearly injection for HIV prevention that's 99% effective. At $14,000 per injection in the US, proceeds help fund access in resource-limited countries where it can be distributed like a vaccination. Dr. Dawn discusses Journavx (suzetrigine), a new non-opioid pain medication working on sodium channels to block pain signals before reaching the brain. At $30 for 50 pills on GoodRx, it offers an alternative for surgical pain in patients with addiction history or genetic vulnerability to opioid dependence. She details the landmark case of Baby KJ, the first person to receive personalized CRISPR gene therapy. Born with a CPS1 enzyme deficiency causing toxic ammonia buildup, KJ was too small for liver transplant. Scientists identified his specific mutation and used CRISPR base editing delivered via lipid nanoparticles to correct a single DNA letter—changing an A to G—in his liver cells which restored enough function to be discharged home. Dr. Dawn reports surprising findings that COVID mRNA vaccines amplify cancer immunotherapy. Lung cancer patients who received COVID vaccination within 100 days of checkpoint inhibitor treatment had 56% three-year survival versus 31% for unvaccinated patients. The mechanism is unknown but may involve mRNA generally alerting the immune system. She revisits research showing Zostavax shingles vaccination reduced dementia risk by 20% over seven years. A natural experiment in Wales—where an age cutoff created comparable vaccinated and unvaccinated groups—provided strong evidence that preventing herpes zoster inflammation protects brain health. Dr. Dawn concludes with Huntington's disease breakthrough: microRNA therapy delivered by virus directly into the brain slowed disease progression by 75% over three years. The microRNA binds to Huntington protein mRNA, preventing ribosome translation and toxic protein production. Some patients returned to work; others expected to need wheelchairs are still walking.

Many listeners asked us to go deeper into exosomes, and this episode expands on everything that most brands avoid talking about: count, consistency, purity, and microRNA composition. We explain why exosomes on a label don't mean much without verified numbers, and how dose shapes whether the skin actually receives a biologically meaningful message.We walk through why platelet-derived exosomes offer the clearest communication to human skin, why microRNAs matter more than growth factors alone, and how publishing full sequencing data creates a new standard for transparency in longevity skincare. We also explore the synergy between exosomes and NAD+, how cellular energy drives repair, and why combining messenger and fuel creates a regenerative loop the skin can sustain.This episode gives listeners a clear, science-driven understanding of how exosome formulas should be evaluated and what truly defines high-performance regenerative skincare.As founders of Young Goose Skincare, we focus on bringing advanced longevity science into daily routines through transparency, validated potency, and clinically guided innovation.We Also Discuss:(00:19) Why “Exosomes on the Label” Tells You Almost Nothing(01:48) The Dose Problem: How Most Exosome Serums Miss Biological Activity(03:11) Why microRNA is the Real Engine Behind Skin Repair(05:16) The Transparency Gap in Skincare, and How We're Closing It(09:21) Exosomes as Messages, NAD+ as the Battery(12:21) Clearing Senescent Cells and Restoring Youthful FunctionFind more from Young Goose:VAMPIRE EXOSOMES → Professional Exosome Serum for Regeneration and Post-Treatment Recovery → Vampire ExosomesUse code PODCAST10 to get 10% off your first purchase, and if you're a returning customer use the code PODCAST5 to get 5% off at https://www.younggoose.com/ Instagram: @young_goose_skincare

Send us a textIn this episode of Vet Life Reimagined, Dr. Eve Hanks, BVM&S, CertAVP (EM), PhD, FRCVS, takes us inside the emerging world of microRNA diagnostics, a technology that could transform how veterinarians detect and manage disease across species.Dr. Hanks' journey is remarkable: from becoming a single mom at 19, to mixed animal practice, to discovering a passion for research, and ultimately founding MiRNA, a biotech company advancing early-detection diagnostics in animals.Eve explains what microRNAs are, why they represent a major leap forward in precision medicine, and how this technology may allow veterinarians to identify chronic disease earlier and improve outcomes for both companion and production animals. She also shares honest insights about leadership, resilience, and what it really takes to build a mission-driven company from the ground up.This conversation blends science, innovation, and career inspiration — a must-listen for anyone curious about the future of veterinary medicine.Resources:Episode on YouTubeMiRNA websiteMiRNA on LinkedInGet your gift guide here. Support the showMore Vet Life Reimagined?

Dr. Pedro Barata and Dr. Aditya Bagrodia discuss the evolving landscape of testicular cancer survivorship, the impact of treatment-related complications, and management strategies to optimize long-term outcomes and quality of life. TRANSCRIPT:  Dr. Pedro Barata: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I'm Dr. Pedro Barata. I'm a medical oncologist at University Hospitals Seidman Cancer Center and associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. We all know that testicular cancer is a rare but highly curable malignancy that mainly affects young men. Multimodal advances in therapy have resulted in excellent cancer specific survival, but testicular cancer survivors face significant long term treatment related toxicities which affect their quality of life and require surveillance and management. With that, I'm very happy today to be joined by Dr. Aditya Bagrodia, a urologic oncologist, professor, and the GU Disease Team lead at UC San Diego[KI1]  Health, and also the lead author of the recently published paper in the ASCO Educational Book titled, "Key Updates in Testicular Cancer: Optimizing Survivorship and Survival." And he's also the host of the world-renowned BackTable Urology Podcast. Dr. Bagrodia, I'm so happy that you're joining us today. Welcome. Dr. Aditya Bagrodia: Thanks, Pedro. Absolutely a pleasure to be here. Really appreciate the opportunity. Dr. Pedro Barata: Absolutely.  So, just to say that our full disclosures are available in the transcript of this episode.  Let's get things started. I'm really excited to talk about this. I'm biased, I do treat testicular cancer among other GU malignancies and so it's a really, really important topic that we face every day, right? Fortunately, for most of these patients, we're able to cure them. But it always comes up the question, "What now? You know, scans, management, cardio oncology, what survivorship programs we have in place? Are we addressing the different survivorship piece, psychology, fertility, et cetera?" So, we'll try to capture all of that today. Aditya, congrats again, you did a fantastic job putting together the insights and thoughts and what we know today about this important topic. And so, let's get focused specifically about what happens when patients get cured. So, many of us, in many centers, were fortunate enough to have these survivorship programs together, but I find that sometimes from talking to colleagues, they're not exactly the same thing and they don't mean the same thing to different people, to different institutions, right? So, first things first. What do you tell a patient perhaps when they ask you, "What can happen to me now that I'm done with treatment for testicular cancer?" Whether it's chemotherapy or just surgery or even radiation therapy? "So, what about the long term? What should I expect, Doctor, that might happen to me in the long run?" Dr. Aditya Bagrodia: Totally. I mean, I think that question's really front and center, Pedro, and really appreciate you all highlighting this topic. It was an absolute honor to work with true thought leaders and the survivorship bit of it is front and center, in my opinion. It's really the focus, you know, we, generally speaking should be able to cure these young men, but it's the 10, 15, 20 years down the way that they're going to largely contend with. The conversation really begins at diagnosis, pre-education. Fortunately, the bulk of patients that present are those with stage one disease, and even very basic things like before orchiectomy, talking about a prosthetic; we know that that can impact body image and self esteem, whether or not they decide to receive it or not. Actually, just being offered a prosthetic is important and this is something, you know, for any urologist, it's kind of critical. To discussing fertility elements to this, taking your time to examine the contralateral testicle, ask about fertility problems, issues, concerns, offer sperm banking, even in the context of a completely normal contralateral testicle, I think these things are quite important.  So if it's somebody with stage one disease, you know, without going too far down discussing adjuvant therapy and so forth, I will start the conversation with, "You know, the testes do largely two things. They make testosterone and they make sperm." By and large, patients are going to be able to have acceptable levels of testosterone, adequate sperm parameters to maintain kind of a normal gonadal state and to naturally conceive, should that be something they're interested in. However, there's still going to be, depending on what resource you look at, somewhere in the order of 10-30% that are going to have issues. Where I think for the stage one patients, it's really incumbent upon us is actually to not wait for them to discuss their concerns, particularly with testosterone, which many times can be a little bit vague, but to proactively ask about it every time. Libido, erectile quality, muscle mass maintenance, energy, fatigue. All of these are kind of associated symptoms of hypogonadism. But for a lot of kids 18-20 years old, it's going to be something insidious that they don't think about. So, for the stage one patients, it absolutely starts with gonadal function. If they are stage two getting surgery, I think the counseling really needs to center around a possibility for ejaculatory dysfunction. Now, for a chemotherapy-naive, nerve-sparing RPLND, generally these days we should be able to preserve ejaculatory function at high volume centers, but you still want to bring that up and again kind of touch base on thinking about sperm banking and so forth before the operation, scars, those are things I think worth talking about, small risk of ascites. Then, I think the intensity of potential long term adverse effects really ramps up when we're talking about systemic therapy, chemotherapy. And then there's of course some radiation therapy specific elements that come up. So, for the chemotherapy bits of it, I really think this is going to be something that can be a complete multi-system affected intervention. So, anxiety, depression, our group has actually shown using some population resources that even suicidality can be increased among patients that have been treated for germ cell tumor. You know, really from the top down, tinnitus, hearing changes, those are things that we need to ask about at every appointment. Neuropathy, sexual health, that we kind of talked about, including ED (erectile dysfunction), vertigo, dizziness, Raynaud's phenomenon, these are kind of more the symptoms that I think we need to inquire about every time. And what we do here and I think at a lot of survivorship programs is use kind of a battery of validated instruments, germ cell tumor specific, platinum treated patient specific. So we use a combination of EORTC questions and PROMIS questions, which actually serves as like a review of systems for the patient, also as a research element. We review that and then depending on what might be going on, we can dig into that further, get them over to colleagues in audiology or psychology, et cetera.  And then of course, screening for the hypertension, hyperlipidemia, metabolic syndrome with basically you or myself or somebody kind of like us serving, many times it's the role of the PCP, just making sure we're checking out, you know, CBC, CMP, et cetera, lipid parameters to screen for those kind of cardiac associated issues along with secondary malignancies. Dr. Pedro Barata: So that's super comprehensive and thorough. Thank you so much. Actually, I love how you break it down in a simple way. Two functions of the testes, produce testosterone and then, you know, the problem related to that is the hypogonadism, and then the second, as you mentioned, produce sperm and of course related to the fertility issues with that.  So, let's start with the first one that you mentioned. So, you do cite that in your paper, around 5-10% of men end up getting, developing hypogonadism, maybe clinical when they present with symptoms, maybe subclinical. So, I'm wondering, for our audience, what kind of recommendations we would give for addressing that or kind of thinking of that? How often are you ordering those tests? And then, when you're thinking about testosterone replacement therapy, is that something you do immediately or are there any guidelines into context that? How do you approach that? Dr. Aditya Bagrodia: So, just a bit more on digging into it even in terms of the questions to ask, you know, "Do you have any decrease in sexual drive? Any erectile dysfunction? Are your morning erections still taking place? Has the ejaculate volume changed? Physically, muscle mass, strength? Have you been putting on weight? Have you noticed increase in body fat?" And sometimes this is complicated because there's some anxiety that comes along with a cancer diagnosis when you're 20, 30 years old, multifactorial, hair loss, hot flashes, irritability. Sometimes they'll, you know, literally they'll say, "You know, my significant other or partners noticed that I'm really just a little bit labile." So I think, you know, there's the symptoms and then checking, usually kind of a gonadal panel, FSH, LH, free and total testosterone, sex hormone binding globulin, that's going to be typically pretty comprehensive. So if you've got symptoms plus some laboratory work, and ideally that pre-orchiectomy testosterone gives you some delta. If they started out at an 800, 900, now they're 400, that might be a big change for them. And then, when you talk about TRT (Testosterone Replacement Therapy) recommendations, you know, Pedro, yourself, myself, we're kind of lucky to be at academic centers and we've got men's health colleagues that are ultra experts, but at a high level, I would say that a lot of the TRT options center around fertility goals. Exogenous testosterone treats the low T, but it does suppress gonadal function, including spermatogenesis. So if that's not a priority, they can just get TRT. It should be done under the care of a urologist, a men's health, an endocrinologist, where we're checking liver chemistries and CBCs and a PSA and so forth. If they're interested in fertility preservation, then I would say engaging an endocrinologist, men's health expert is important. There's medications even like hCG, Clomid, which works centrally and stimulate the gonadal access. Niche scenarios where they might want standard TRT now, and then down the way, 5, 7 years, they're thinking about coming off of that for fertility purposes, I think that's really where you want to have an expert involved because there's quite a bit of nuance there in recovery of actual spermatogenesis and so forth.  To kind of summarize, you got to ask about it. Checking it is, is not overly complicated. We do a baseline pre-orchiectomy and at least once annually, you can tag it in with the tumor markers, so it's not an extra blood draw. And if they have symptoms of course, kind of developed, then we'll move that up in the evaluation. Dr. Pedro Barata: Got it. And you also touch base on the fertility angle, which is truly important. And I'm just curious, you know, a lot of times many of us might see one, two patients a year, right, and we forget these protocols and what we've got to do about that.  And so I'm interested to hear your thoughts about when you think about fertility, and how proactive you get. In other words, who do you refer for the fertility clinic, for a fertility preservation program? You know, do all cases despite getting through orchiectomy or just the cases that you're going to, you know you're going to seek chemotherapy at some point? What kind of selection or it depends on the chemo, like how do you do that assessment about the referral for preservation program that you might have available at UCSD? Dr. Aditya Bagrodia: Yeah, I mean I feel really fortunate to sit on the NCCN Testis Cancer Guidelines. It's in there that fertility counseling should be discussed prior to orchiectomy. So 100% bring it up. If there are risk factors, undescended testicles, previous history of fertility concerns, atrophic contralateral testicle, anything on the ultrasound like microlithiasis in the contralateral testicle, you kind of wanna get it there. And then again, there's kind of niche scenarios where you're really worried, maybe get a semen analysis and it doesn't look that good, arrange for the time of orchiectomy to have onco-testicular sperm extraction from the, quote unquote, "normal" testis parenchyma. You know, I think you have to be kind of prepared to go that route and really make sure you're doing this completely comprehensively.  So pre-orchiectomy all patients. Don't really push for it too hard if they've got a contralateral testicle, if they've had no issues having children. There's some cost associated with this, sperm banking still isn't kind of covered even in the context of men with cancer. If they've got risk factors, absolutely pre-orchiectomy. Pre-RPLND, even though the rates of ejaculatory dysfunction at a high-volume center should be low single digits, I'll still offer it. That'd be a real catastrophe if they were in that small proportion of patients and now they're going to be reliant on things like intrauterine insemination, where it becomes quite expensive.  Pre-chemo, everybody. That's basically a standard these days where it should be discussed and it's kind of amazing currently, even if you don't have an accessible men's health fertility clinic, there are actually companies, I have no vested interest, Fellow is one such company where you can actually create an account, receive a FedEx semen analysis and cryopreservation kit, send it back in, and all CLIA certified, it's based out of California. The gentleman that runs it, is a urologist and very, very bright guy who's done a lot of great stuff for testis cancer. So, even for patients that are kind of in extremis at the hospital that kind of need to get going like yesterday, we still discuss it. We've got some mechanisms in place to either have them take a semen analysis over to our Men's Health clinic or send it off to Fellow, which I think is pretty cool and that even extends to some of our younger adolescent patients where going to a clinic and providing a sample might be tricky.  So, I think bringing it up every stage, anytime there's an intervention that might be offered, orchiectomy, chemo, surgery, radiation, it's kind of incumbent on us to discuss it. Dr. Pedro Barata: Gotcha. That's super helpful. And you also touch base on another angle, which is the psychosocial angle around this. You mentioned suicidal rates, you mentioned anxiety, perhaps depression in some cases as well as chronic fatigue, not necessarily just because of the low testosterone that you can get, but also from a psychological perspective. I'm curious, what do the recommendations look like for that? Do these patients need to see a social worker or a psychologist, or do they need to answer a screening test every time they come to see us and then based on that, we kind of escalate, take the next steps according to that? Do they see a psychologist perhaps every so often? How should that be managed and addressed? Dr. Aditya Bagrodia: It's an excellent question and again, these can be rather insidious symptoms where if you don't really dig in and inquire, they can be glossed over. I mean, how easy to say, "Your markers look okay, your scans look okay. See you in six months," and keep it kind of brief. First off, I think bringing it up proactively and normalizing it, that, "This may be something that you experience. Many people do, you're not alone, there's nothing kind of wrong with you." I also think that this is an area where support groups can be incredibly useful. We host the Testicular Cancer Awareness Foundation support group here. They'll talk about chemo brain or just like a little bit of an adjustment disorder after their diagnosis. Support groups, I think are critical. As I mentioned, we have a survivorship program that's led by a combination of our med oncs, myself on the uro-onc side, as well as APPs, where we are systematically asking about essentially the whole litany of issues that may arise, including psychosocial, anxiety, depression, suicidality. And we've got a nice kind of fast path into our cancer center support services for these young men to meet with a psychologist. If that isn't going to be sufficient, they can actually see a psychiatrist to discuss medications and so forth. I do think that we've got to screen for these because, as anticipated from diagnosis, those first 2 years, we see a rise. But even 10, 15 years out, we note, compared to controls, that there is an increased level of anxiety, depression, suicidality that might not just take place at that initial acute period of diagnosis and treatment. Dr. Pedro Barata: Really well said. Super important.  So I guess if I were to put all these together, with these really amazing advances in technology, we all know AI, some of us might be more or less aware of biomarkers coming up, including microRNA for example, and others, like as I think of all these potential long term complications for these patients, look at the future, I guess, can we use this as a way to deescalate treatment where it's not really necessary, as a way to actually prevent some of these complications? Like, how do we see where we're heading? As we manage testicular cancer, let's say, within the next 5 or 10 years, do you think there's something coming up that's going to be different from what we're doing things today? Dr. Aditya Bagrodia: Totally. I mean, I think it's as exciting as a time as there's ever been, you know, maybe notwithstanding circa 1970s when platinum was discovered. So microRNAs, which you mentioned, you know, there's a new candidate biomarker, microRNA-371. We are super excited here at UCSD. We actually have it CLIA-certified available in our lab and are ordering these tests for patients kind of in their acute stage, you know, stage one and surveillance, stage two, post-RPLND, receiving chemotherapy. And essentially this is a universal germ cell tumor specific biomarker, except for teratoma, suffice it to say 90% sensitive and specific. And I think it's going to change the way that we diagnose and manage patients. You know, pre-orchiectomy, that's pretty straightforward. Post-orchiectomy, maybe we can really decrease the number of CT scans that are done. Maybe we can identify those patients that basically have occult disease where we can intervene early, either with RPLND or single cycle chemo. Post-RPLND, identify the patients who are at higher risk of relapse that may benefit from some adjuvant therapy. In the advanced setting, look at marker decline for patients in addition to standard tumor markers. Can we modulate their systemic therapy?  So, the international interest is largely on modifying things. There's really cool clinical trials that we have for stage one patients, that treatment would be prescribed based on a post-orchiectomy microRNA. I think the microRNAs are really exciting. Teratoma remains an outstanding question. I think this is where maybe ctDNA, perhaps some radiomics and advanced imaging processing and incorporating AI may allow us to safely avoid a lot of these post-chemo RPLNDs. And then identification using SNPs and so forth of who might be most susceptible to some of the cardiac toxicity, autotoxicity and personalizing things in that way as well. Dr. Pedro Barata: Super exciting, right, what's about to come? And I agree with you, I think it's going to change dramatically how we manage this disease.  This has been a pleasure sitting down with you. I guess before letting you go, anything else you'd like to add before we wrap it up? Dr. Aditya Bagrodia: Yeah, first off, again, just want to thank you and ASCO for the opportunity. And it's easy enough to, I think, approach a patient with the testicular germ cell tumor as, "This is an easy case. We're just going to do whatever we've done. Go to the guidelines that says do X, Y, or Z." But there's so much more nuance to it than that. Getting it done perfectly, I think, is mandatory. Whatever we do is an impact on them for the next 50, 60, 70 years of their life. And I found the germ cell tumor community, people are really passionate about it. If you're ever uncertain, there's experts throughout the country and internationally. Ask somebody before you do something that you can't undo. I think we owe it to them to get it perfect so that we can really maximize the survivorship and the survival like we've been talking about. Dr. Pedro Barata: Aditya, thanks for sharing your fantastic insights with us on this podcast. Dr. Aditya Bagrodia: All right, Pedro. Fantastic. Appreciate the opportunity. Dr. Pedro Barata: And also, thank you to our listeners for your time today. I actually encourage you to check out Dr. Bagrodia's article in the 2025 ASCO Educational Book. We'll post a link to the paper in the show notes. Remember, it's free access online, and you can actually download it as well as a PDF. You can also find on the website a wealth of other great papers from the ASCO Educational Book on key advances and novel approaches that are shaping modern oncology.  So with that, thank you everyone. Thank you, Aditya, one more time, for joining us. Thank you, have a good day. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:         Dr. Pedro Barata  @PBarataMD   Dr. Aditya Bagrodia @AdityaBagrodia Follow ASCO on social media:         @ASCO on X (formerly Twitter)         ASCO on Bluesky        ASCO on Facebook         ASCO on LinkedIn         Disclosures:      Dr. Pedro Barata:  Stock and Other Ownership Interests: Luminate Medical  Honoraria: UroToday  Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon  Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas  Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck   Dr. Aditya Bagrodia: Consulting or Advisory Role: Veracyte, Ferring  

Broadcast from KSQD, Santa Cruz on 10-30-2025: Dr. Dawn opens with Halloween-themed scary medical stories, beginning with food toxins lurking in refrigerators and pantries. She explains how molds on grains and nuts, particularly Aspergillus species, produce aflatoxins that bind to DNA and cause liver cancer, making peanuts especially risky. Fusarium on wheat produces trichothecenes and fumonisins damaging cell membranes. Penicillium molds on fruits like apples produce patulin creating reactive oxygen species that harm organs. She advises discarding soft moldy foods entirely since fungal hyphae penetrate deeply, while hard cheeses can have moldy portions cut away. Meat spoilage involves bacteria producing cadaverine and putrescine, with E. coli, Campylobacter, Salmonella, and Clostridium causing severe illness through heat-stable toxins. A caller asks about yogurt-covered peanuts tasting rancid and confirms Botox contains botulinum toxin A in different salt forms, used medically for migraines, hyperhidrosis, and strabismus. The caller also describes paper-thin skin on sun-exposed forearms that bleeds easily. Dr. Dawn explains UV radiation damages collagen and elastin, making blood vessels vulnerable to shear forces. She recommends topical vitamin K products like Dermal K and protective lycra sleeves or gardening gauntlets to prevent injuries, emphasizing the need for annual dermatologic exams after extensive sun exposure. An emailer asks about RSV vaccine recommendations before overseas travel. Dr. Dawn disagreed with the couple's physician, citing US Preventive Services Task Force guidelines recommending RSV vaccination for all adults 60 and older, plus those 50+ with chronic conditions. She discusses FDA-approved home testing options including the PIXEL by LabCorp test for COVID, flu, and RSV, and iHealth rapid tests. She notes RSV point-of-care tests are available to medical practitioners and recommends thorough vaccination before international trips. Dr. Dawn presents a frightening investigation into private equity hospital bankruptcies, focusing on Steward Healthcare's 31 hospitals and Prospect's 16 facilities. Private equity firm Cerberus earned $700 million while Steward 650 documented incidents of deficient care including deaths. One woman died from hemorrhage after vendors repossessed equipment due to unpaid bills. She explains the shell game where companies sell hospital land to Medical Properties Trust, forcing new operators to pay rent while private equity extracts profits. The Brookings Institution study reveals systematic prioritization of investor returns over patient care, with courts failing to prevent these practices despite some states passing protective legislation. She discusses stillbirth rates being significantly underreported, with Harvard research showing actual rates of 1 in 147 pregnancies versus CDC's 1 in 175, worsening to 1 in 95 for black families. Over 70% involved known risks like obesity or diabetes, but 30% had no identifiable factors. Dr. Dawn emphasizes unconscious bias in medicine where women's complaints are dismissed, particularly affecting women of color and non-English speakers, noting both patient and provider biases require training to address. Dr. Dawn warns about HPV-related oral squamous cell carcinoma in young men, explaining that changing sexual practices over 30 years have created new transmission routes from genitals to mouth. Major risk factors include smokeless tobacco and hard alcohol which damage DNA. She mentions newly available saliva tests for persistent HPV detection, recommending risk factor reduction for positive cases. She concludes optimistically with a breakthrough Huntington's disease treatment using microRNA molecule AMT-130 delivered via virus to brain striatum. The treatment mirrors toxic Huntington protein's RNA, creating double-stranded structures cells destroy, preventing toxic protein accumulation. The three-year trial of 29 patients showed 75% slowing of disease progression with few side effects, offering hope for 100,000 Americans carrying the mutation, including 40,000 with current symptoms.

Exosomes aren't just a buzzword, they're nanoscale messengers that deliver the body's own repair instructions. In this episode of Biohacking Beauty, we unpack the science of platelet-derived, or “vampire,” exosomes and how they go beyond conventional growth factors to target aging at its root. You'll learn how microRNA inside platelet exosomes can reduce senescence signals, trigger collagen and elastin renewal, and activate autophagy for deeper cellular repair. The hosts also explore how formulation stability, ingredient compatibility, and third-party quantification make or break an exosome product. If you've ever wondered how PRP exosomes compare to traditional PRP facials, or why pairing them with NAD-boosting actives can amplify skin longevity, this episode explains the real mechanisms behind the hype, helping you understand what it takes for skin to truly act younger, not just look it.What's Discussed:(00:00) Redefining Skin Longevity Through Cellular Repair(06:07) How Exosomes Became the Next Frontier in Regenerative Skincare(16:00) Why Platelet-Derived Exosomes Deliver the Most Potent Repair Signals(23:54) The Real Anti-Aging Data Behind PRP Exosomes(32:35) Exosomes vs. Retinoids, Fillers, and Lasers, What the Evidence Shows(46:30) Elevating Repair Capacity: Exosomes Meet Rejuve NADFind more from Young Goose:Vampire Exosomes: Experience the world's highest-potency exosome serum here → Vampire ExosomesUse code PODCAST10 to get 10% off your first purchase, and if you're a returning customer use the code PODCAST5 to get 5% off at https://www.younggoose.com/ Instagram: @young_goose_skincare

Send us a textAfter a two-week hiatus dealing with shipping challenges and postal strikes, Jason and Chris return with exciting scientific breakthroughs and heartwarming pet insights. Their absence was filled with stuffy reshipping adventures and a memorable Comic-Con appearance with their super-dog companions.The episode features a remarkable development in Huntington's disease treatment – a devastating neurodegenerative condition affecting 7 in 100,000 people worldwide. A pioneering gene therapy trial using microRNA delivered via viral vectors directly to the brain has shown unprecedented success in slowing disease progression. Patients receiving the highest dose demonstrated 75% less decline in cognitive and motor symptoms compared to untreated individuals. While invasive and still pending regulatory approval, this breakthrough offers genuine hope for patients and families who've endured decades of despair. Beyond Huntington's, this approach could potentially revolutionize treatments for other neurodegenerative diseases like Parkinson's.The pet science segment reveals fascinating research about canine cognition, particularly how "gifted" dogs mentally categorize toys by function rather than appearance. Border collies demonstrated an ability to classify toys based solely on how they're used in play – whether for throwing or tugging – without relying on verbal cues. This suggests dogs possess cognitive flexibility comparable to human toddlers, understanding not just words but concepts. The study highlights how our canine companions don't merely memorize but actually comprehend and apply knowledge functionally, raising profound questions about their cognitive abilities.Our all links to social media and more!Support the showFor Science, Empathy, and Cuteness!Being Kind is a Superpower.https://twitter.com/bunsenbernerbmd

This week, Shawn Wilkie and Dr. Ivan Zak meet with Dr. Eve Hanks, the founder of MI:RNA Diagnostics to chat about her remarkable journey from clinical veterinary practice to becoming the CEO of a pioneering diagnostics company. Eve shares how her background in immunology led to the creation of an AI-powered platform that uses microRNA to detect disease earlier than ever before. You`ll discover how predictive diagnostics can improve clinical decision-making, reduce uncertainty, and support personalized care for both pets and production animals.   Learn more about MI:RNA Diagnostics. Dr. Hanks recommends “The Body Keeps the Score: Brain, Mind, and Body in the Healing of Trauma” by Bessel van der Kolk M.D.

I muscoli non servono solo a muoversi: sono veri e propri organi endocrini!Nel nuovo episodio del nostro podcast parliamo di come l'allenamento con i pesi influenzi il metabolismo, l'appetito e persino il funzionamento del cervello.Scopriremo che sostanze come il lattato, le miochine e i microRNA trasformano il muscolo in un alleato contro obesità e diabete, e perché ogni esercizio in palestra è anche un atto di prevenzione.

BUFFALO, NY - July 18, 2025 – A new #editorial was #published in Volume 16 of Oncotarget on July 16, 2025, titled “microRNAs in soft tissue sarcoma: State of the art and barriers to translation.” In this article, Elizaveta K. Titerina, Alessandro La Ferlita, and Joal D. Beane from Ohio State University discuss the role of microRNAs in soft tissue sarcomas (STS), a rare and diverse group of cancers that begin in connective tissues, like bone or fat. The authors explain how these small molecules regulate cancer-related processes and highlight their potential as non-invasive biomarkers for diagnosis and monitoring. They also outline the main challenges that need to be addressed before microRNA-based strategies can be used in clinical settings. Soft tissue sarcomas include over 50 subtypes, making precise diagnosis and effective treatment difficult. The editorial describes how microRNAs influence cancer growth, spread, and response to therapies. Because microRNAs are stable in body fluids like blood and saliva, they could be used for early detection and to help guide treatment decisions. Such as, certain groups of microRNAs are linked to how patients respond to specific drugs, showing their potential as tools for precision medicine. “For example, miR-17-92 and miR-106b-25 clusters have been associated with sensitivity or resistance to eribulin in STS.” The authors also explain that microRNAs could help distinguish between tumor types that are often difficult to differentiate, such as benign lipomas and malignant liposarcomas. Recognizing these differences is crucial for guiding treatment decisions. Specific patterns of microRNA expression in blood samples may enable clinicians to make quicker and more reliable diagnoses without the need for invasive procedures. Beyond their diagnostic role, microRNAs are also being explored as therapeutic tools, but applying microRNA-based therapies to patients remains challenging. These molecules can act as either cancer promoters or suppressors, depending on the environment, which complicates the development of safe and targeted treatments. However, new delivery methods such as lipid nanoparticles show promise in improving precision and safety. Overall, microRNAs are emerging as an important focus in STS research, offering new possibilities for advancing diagnosis, prognosis, and treatment. As researchers continue to address the current challenges, these small molecules could become valuable tools in improving cancer care. DOI - https://doi.org/10.18632/oncotarget.28754 Correspondence to - Joal D. Beane, joal.beane@osumc.edu Video short - https://www.youtube.com/watch?v=MlLGA8BObPQ Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28754 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, soft tissue sarcoma, liposarcoma, microRNA, small non-coding RNA, cancer biomarkers To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

In this episode of It Takes Balls, Dr. Nabil Adra, a medical oncologist at Indiana University Health and leading researcher in testicular cancer care explores everything from recurrence and refractory disease to the latest advancements in treatment and monitoring.Dr. Adra breaks down risk categories that guide treatment - good, intermediate, and poor - and explains how factors like tumor type and blood markers shape decisions about chemo, surgery, or surveillance. He also dives into the science behind relapse and platinum resistance.A major highlight of the episode is the discussion of innovative diagnostic tools like circulating tumor DNA (ctDNA) and microRNA-371. These biomarkers are making it possible to detect microscopic cancer earlier and more accurately, with the goal of reducing overtreatment and improving outcomes.Dr. Adra also shares insights on long-term monitoring, including the reality of late relapse, and emphasizes why annual checkups are crucial - even decades after treatment. For those with relapsed or refractory disease, he offers a hopeful look at cutting-edge therapies including targeted treatments, high-dose chemo, and upcoming CAR-T cell trials.Have a question for a future expert guest? Submit here:https://www.testicularcancerawarenessfoundation.org/it-takes-balls-question-submissionWant to be a guest? Apply here:https://www.testicularcancerawarenessfoundation.org/it-takes-balls-submissionsFollow Testicular Cancer Awareness Foundation:⁠https://www.testescancer.orghttps://www.twitter.com/testescancer⁠⁠https://www.instagram.com/testescancerhttps://www.facebook.com/tca.orgEmail Dr. Adra:nadra@iu.eduFollow Steven Crocker: https://www.twitter.com/stevencrockerhttps://www.instagram.com/stevencrockerhttps://www.facebook.com/steven.crocker2Theme song: No Time Like Now - Tom Willner www.tomwillner.com

Diagnosticare il cancro con un esame del sangue: ancora non ci siamo, ma quel giorno potrebbe non essere così lontano. E tra i progetti che mirano questo obiettivo ora c’è anche STELLAR: ideato da Laura Fabris, oggi al Politecnico di Torino, mira a dar vita a un test che permetta di diagnosticare precocemente il tumore alla prostata (nello specifico caso con un esame delle urine) e successivamente altri tumori grazie alle analisi del sangue. Il gruppo di Fabris è specializzato nella fabbricazione di particolari nanoparticelle a forma di stella, dotate di numerose proprietà peculiari, che utilizzerà in questo caso per attirare e concentrare su sé stesse degli specifici frammenti di microRNA rilasciati dalle cellule tumorali, presenti nei fluidi corporei ma in concentrazioni fin qui troppo basse per essere analizzati. Ne parliamo, appunto, con Laura Fabris, Professoressa di Fisica al Dipartimento di Scienze Applicate e Tecnologia del Politecnico di Torino.

Victor Ambros, newly awarded the Nobel Prize for his discovery of microRNA, is a developmental biologist at the University of Massachusetts Medical School. In this episode, we explore improvisational science – the dynamic, collaborative process where researchers build on each other's ideas using a "yes, and…" approach. We discuss the constant need to reframe and refine scientific questions, and the challenge of helping young researchers build the confidence to question established ideas. Victor underscores the power of curiosity-driven research, emphasizing how each scientist's unique perspective can lead to discoveries others might miss. We also examine AI's evolving role in scientific discovery – particularly in synthesizing knowledge across disciplines – and how it can complement the cross-pollination of ideas at scientific conferences.For more information about Night Science, visit https://www.biomedcentral.com/collections/night-science .

Winners of the 2024 Nobel Prize in Physiology or Medicine Dr. Victor Ambros and Dr. Gary Ruvkun give a rare, extended joint interview about the road that led them to their discovery of miRNA in a roundworm, Dr. Ruvkun's later discovery of miRNA in humans, how the scientists were both inspired at a young age by astronomy, what Dr. Ambros' late father might have said about his son's Nobel win, and a decades-old story from Dr. Ruvkun about a trip to Bolivia.

面膜團購日期： 2024/11/7-11/19 不定期會開補貨團喔！ 加入團購群吧！很多好東西都在這裡

Broadcast from KSQD, Santa Cruz on 10-17-2024: Dr. Dawn addresses a listener's question about optimal timing for the consumption of iron, green tea, and nori powder to maximize absorption, recommending timing and supplementation strategies. She responds to a listener's email on the issue of plastic in tea bags and provides resources for finding plastic-free options, while also clarifying misconceptions about microplastics in seaweed and fish. Dr. Dawn celebrates the Nobel Prize in Physiology and Medicine awarded for the discovery of micro RNA, explaining its significance in gene regulation and potential therapeutic applications. She highlights a major neuroscience milestone: the mapping of a fruit fly's brain connectome, discussing its implications for understanding complex behaviors and neural circuits. Dr. Dawn provides comprehensive advice for managing ulcerative colitis, including vitamin D supplementation, CBD, omega-3 fatty acids, and stress reduction techniques. She discusses a study on pythons that could lead to new therapies for heart disease, explaining how the snake's unique cardiac adaptations might inform human treatments. Dr. Dawn introduces the Ronnie Gardner method, a music-based movement therapy showing promise in rehabilitation for stroke and Parkinson's disease patients.

Broadcast from KSQD, Santa Cruz on 10-17-2024: Dr. Dawn addresses a listener's question about optimal timing for the consumption of iron, green tea, and nori powder to maximize absorption, recommending timing and supplementation strategies. She responds to a listener's email on the issue of plastic in tea bags and provides resources for finding plastic-free options, while also clarifying misconceptions about microplastics in seaweed and fish. Dr. Dawn celebrates the Nobel Prize in Physiology and Medicine awarded for the discovery of micro RNA, explaining its significance in gene regulation and potential therapeutic applications. She highlights a major neuroscience milestone: the mapping of a fruit fly's brain connectome, discussing its implications for understanding complex behaviors and neural circuits. Dr. Dawn provides comprehensive advice for managing ulcerative colitis, including vitamin D supplementation, CBD, omega-3 fatty acids, and stress reduction techniques. She discusses a study on pythons that could lead to new therapies for heart disease, explaining how the snake's unique cardiac adaptations might inform human treatments. Dr. Dawn introduces the Ronnie Gardner method, a music-based movement therapy showing promise in rehabilitation for stroke and Parkinson's disease patients.

Victor Ambros and Gary Ruvkun were awarded the 2024 Nobel prize in physiology or medicine for their discovery of microRNA, tiny biological molecules that tell the cells in our body what kind of cell to be by turning on and off certain genes.In this episode, we speak to Ambros, who is professor of natural sciences at UMass Chan Medical School in the US, about the discovery that led to his Nobel prize and find out what he's researching now. And we hear from Justin Stebbing, professor of biomedical sciences at Anglia Ruskin University in the UK, about how a deeper understanding of microRNA is opening up new avenues for potential treatment of diseases such as cancer. This episode was produced by Gemma Ware, Katie Flood and Mend Mariwany. Sound design was by Michelle Macklem and our theme music is by Neeta Sarl. Full credits for this episode are available. Sign up here for a free daily newsletter from The Conversation.If you like the show, please consider donating to The Conversation, which is an independent, not-for-profit news organisation. And please do rate and review the show wherever you listen.Further reading:MicroRNA − a new Nobel laureate describes the scientific process of discovering these tiny molecules that turn genes on and offMicroRNA is the Nobel-winning master regulator of the genome – researchers are learning to treat disease by harnessing how it controls genesNobel prize in medicine awarded for discovery of microRNAs, the molecules that control our genesFull coverage of the 2024 Nobel prizes on The Conversation Hosted on Acast. See acast.com/privacy for more information.

Ein und ein Viertel Jahrhundert werden die Nobelpreise nun schon vergeben. Dieses Jahr räumt ein super neues Forschungsgebiet zum ersten Mal ab. Und zwar grad doppelt. Wo Physik oder Chemie draufsteht ist nämlich ganz viel Künstliche Intelligenz drin. (00:00) Schlagzeilen (00:35) Eiweiss-Origami mit KI  Die Proteinforschung der diesjährigen drei Chemienobelpreisträger wäre ohne KI nicht möglich gewesen. KI, die in den 1980er Jahren zum Sprung ansetzte und für deren Entwicklung zwei Forscher jetzt den Physiknobelpreis erhalten. John Hopfield und Geoffrey Hinton heissen die beiden Physiknobelpreisträger. Sie wollten verstehen, wie unser Gehirn denkt und brachten Maschinen das Lernen bei. Eine Sensation und gleichzeitig auch Grund für Besorgnis. Selbst für die KI-Pioniere selbst. (08:29) Als die Maschinen denken lernten Künstliche Gehirne beziehungsweise neuronale Netzwerke können viel. Unglaublich viel. Maschinelles Lernen auf der Basis künstlicher neuronaler Netzwerke gelingt heute bereits mit schmalster Kost. Mit minimalen Datenmengen gefüttert lernen Maschinen zu greifen wie eine menschliche Hand oder ausgestattet mit Schnurrhaaren und Rädern wie eine Ratte unbekannte Räume zu erkunden und vieles, vieles mehr. (15:07) MicroRNA leistet mega Grosses In unserem Körper reguliert microRNA die Aktivität von Genen. Sie bremst oder feuert Gene an und sagt den Zellen, wer sie sind: eine Muskelzelle, eine Leberzelle, eine Hirnzelle... MicroRNA ist auch beteiligt an der Entstehung von Krankheiten wie Krebs. Und darin liegt auch eine Chance. Die Wissenschaftler, die dieses Jahr den Medizin-Nobelpreis erhalten, legten mit ihrer Forschung auch den Grundstein für mögliche neue Medikamente. (21:41) Wie gewinnt man einen Nobelpreis Indem man dazugehört. Männlich und weiss zu sein ist eine gute Voraussetzung. Zur richtigen Zeit am richtigen Ort die richtigen Leute zu kennen ebenfalls. Wer in einem Labor eines Wissenschaftlers arbeitet, der bereits einen Nobelpreis erhalten hat, erhöht seine eigenen Gewinnchancen. Ein einziges grosse Netzwerk stellt die meisten Gewinner. Nur ganz vereinzelt kommen Aussenseiterinnen und Aussenseiter an die Pötte. Mehr zum Wissenschaftsmagazin und Links zu Studien: https://www.srf.ch/wissenschaftsmagazin .

A Nobel prize for understanding how genes are turned on and offThe early-morning call from Sweden came on Monday to American molecular biologist Gary Ruvkun for his work in discovering microRNAs, which are essential for regulating genetic activity in plants and animals. Ruvkun says that research based on this work helps us understand basic biology, but has also provided significant insight into disease and might even help us understand whether there is life on other planets. Biologists discover a new microbial world in your bathroomResearchers have found a new biodiversity hotspot. Environmental microbiologist Erica Hartmann and her team sampled showerheads and toothbrushes in ordinary bathrooms, and found a host of bacteria and hundreds of previously unknown viruses. But don't panic: much of this new life are bacteriophages — viruses that infect bacteria — which are harmless to humans and could be potential weapons against the bacteria that can cause human disease. The study was published in the journal Frontiers in Microbiomes.How we might zap an asteroid on a collision course with EarthA new experiment using the world's most powerful radiation source has shown the way to deflecting asteroids with X-rays. The X-rays were used to vaporize some of the surface of a model asteroid, creating a rocket-like effect. Dr Nathan Moore, a physicist at the Sandia National Laboratories in New Mexico, says it's a proof of principle for the concept of deflecting a real asteroid using X-rays generated by a powerful nuclear explosion. The study was published in the journal Nature Physics. Exploring the origins of Australia's iconic, if controversial, wild dogThe Australian Dingo has a fierce reputation as a predator, leading to European settlers attempting to exterminate it in the 19th century. But the dingo's origin story has not been well understood. For years, it was assumed the dingo originated from India, given its similarities to the Indian pariah dog, or from New Guinea. Dr. Loukas Koungolos, a research associate at the University of Sydney, led the study looking at dingo fossils and found out where it likely came from, and how the domestic dogs of ancient people became a wild predator down under. The study was published in the journal Scientific Reports. Can we treat autoimmune disease by manipulating the immune system? Autoimmune diseases like Lupus can be a result of critical immune cells attacking our own bodies. New advances are pointing to ways we might be able to reverse this. Researchers have repurposed a relatively new cancer treatment, called CAR-T therapy that can reprogram immune cells to attack cancer cells, to reset the immune system in patients with lupus to neutralize its autoimmune attack. Dr. Georg Schett and his colleagues, from the Friedrich Alexander University of Erlangen in Germany, were the first to use this immunotherapy to successfully treat lupus patients. That research appeared in the journal Nature Medicine with a follow-up in The New England Journal of Medicine.Other researchers are focussing on understanding — and possibly reversing — what triggers the immune cells to go awry in the first place. Dr. Jaehyuk Choi, from Northwestern University, said they found a molecule that lupus patients are deficient in. In cell culture they demonstrated that correcting this deficiency can reprogram certain immune T-cells to stop directing the attack on the body which they hope could potentially reverse the effects of lupus. His research was published in Nature.

With awards for the discovery of microRNA and the creation of new proteins, plus recognition for artificial intelligence via the physics and chemistry prizes, Madeleine Finlay hears from the Guardian science team – Nicola Davis, Ian Sample and Hannah Devlin – as they break down the news, science and surprises from this year's Nobels. Help support our independent journalism at theguardian.com/sciencepod

La medicina del futuro: microRNA gana Premio Nobel de Medicina: explica Israel PichardoEnlace para apoyar vía Patreon:https://www.patreon.com/julioastilleroEnlace para hacer donaciones vía PayPal:https://www.paypal.me/julioastilleroCuenta para hacer transferencias a cuenta BBVA a nombre de Julio Hernández López: 1539408017CLABE: 012 320 01539408017 2Tienda:https://julioastillerotienda.com/ Te invitamos a que visites nuestro perfil en Patreon. Solo da clic aquí Hosted on Acast. See acast.com/privacy for more information.

On today's podcast, a theater exchange between Japan and Britain brings cultural knowledge; two Americans win the Nobel prize for microRNA discovery; U.S. severe obesity is rising followed by a discussion of ‘prevalent;' then, superlatives on Lesson of the Day.

United States correspondent Todd Todd Zwillich spoke to Lisa Owen about two American biologists being awarded the Nobel Prize in medicine for their work on the discovery of microRNA, and explains what microRNA is.

Morse code transcription: vvv vvv Gary Lineker says BBC contract talks over Match of the Day have just started Mexican mayor murdered days after starting job Nobel Prize goes to microRNA researchers Chris Mason Why it was always likely Sue Gray would go Food rating lies exposed by BBC secret recording Madonna pays tribute to brother Christopher Ciccone House prices close to record high, says Halifax Oasis on the Adriatic where Ukrainians and Russians have gone to escape war Cardiff Half Marathon Runner dies after 2024 race How perfect storm blew away planned social homes England needs

*) UN rights office calls for end to Israel's impunity over Gaza atrocities As Israel's war on Gaza marks a year, the UN warns of widespread violations of international law. Nearly 42,000 have died, and Gaza faces severe displacement, hunger, and disease. The UN stresses accountability is vital to end impunity and the cycle of conflict as Israeli attacks on civilians, schools, and hospitals continue, fueling violence. *) Israel to expand its offensive to south Lebanon coast The Israeli army plans to expand its operations against Hezbollah along Lebanon's coast south of the Awali river. Army spokesperson Avichay Adraee warned civilians to avoid the shore, citing imminent maritime actions. In Israel's northwest, four areas have been declared "closed military zones," restricting access amid heightened tensions on the Lebanon border. *) A year on, Netanyahu has failed families of Israeli hostages Families of hostages held by Hamas gathered near Prime Minister Netanyahu's residence, accusing him of stalling efforts to secure their loved ones' release. About 100 hostages remain in Gaza, many are feared dead. Emotions ran high as families demanded action, with one mother saying, "We won't let you rest until all of them are back." During the gathering, Israel confirmed another hostage's death. *) Shocking surge in Islamophobia as anti-Muslim hatred skyrockets in UK Anti-Muslim hatred in the UK has surged, with Tell MAMA recording 4,971 incidents between October 2023 and September 2024. The NGO's report highlights the rise of verbal abuse, threats and violence, particularly targeting visibly Muslim individuals. Major urban centres, including London, saw the most cases. The group calls for urgent action to curb this growing hostility. *) US researchers win Nobel for cracking gene regulation US scientists Victor Ambros and Gary Ruvkun won the Nobel Prize in Medicine for discovering microRNA, a breakthrough in gene regulation. The Nobel Assembly calls it “a completely new principle” essential for life. The duo celebrated virtually, with Ruvkun excitedly preparing for December's Nobel gala. Their work has significant implications for understanding cell physiology and diseases like cancer.

Hai nhà khoa học Mỹ đã giành giải Nobel về sinh lý học hoặc y học vì phát hiện ra microRNA, những đoạn nhỏ của vật liệu di truyền cung cấp một cách thức, để các nhà khoa học kiểm soát những gì đang xảy ra trong tế bào của chúng ta. Phát hiện của họ có thể dẫn đến những cách mới, để tìm ra và điều trị các bệnh, bao gồm cả ung thư.

Victor Ambros and Gary Rukvun discovered microRNA -- molecules that control how genes regulate each other inside cells. The discovery is the basis for some disease treatments.

Matthias Miersch soll neuer SPD Generalsekretär werden / Zahl der Rentner die in Deutschland auf Sozialhilfe angewiesen sind auf Höchststand / Älteste bekannter Baum Österreichs vor vermeintlichem Lebensende / ESA-Sonde "Hera" soll Asteroiden erreichen und untersuchen / Laut Flüchtlingsagentur der Vereinten Nationen kehren vertriebene Syrer*innen nach Syrien zurück / Australische Regierung sieht sich neuer rechtlichen Herausforderung bei Einwanderungshaftsystem gegenüber / Regierung von New South Wales will bis 2035 jährlich 91 Milliarden Dollar durch Tourismus generieren / Gipfel gegen Verlust der Biodiversität und Zusammenbruch von Ökosystemen im Sydney / Zwei Wissenschaftler gewinnen Medizin-Nobelpreis für Entdeckung von microRNA

Plus: New York City's deputy mayor is the latest aide to Mayor Eric Adams, who has been indicted on corruption charges, to resign. The Nobel Prize for Medicine is awarded to a pair of scientists for their discovery of microRNA, tiny molecules that play an important role in gene regulation. J.R. Whalen reports. Sign up for the WSJ's free What's News newsletter.  Learn more about your ad choices. Visit megaphone.fm/adchoices

“I heard what sounded like an authentic call from the Nobel Committee!” New medicine laureate Gary Ruvkun might have received a prank call or two in the past, but today's was genuine. He talked to the Nobel Prize's Adam Smith minutes after hearing the news, about the pleasure of finding things out, the electrifying growth of the microRNA field over the years, and the benefits of taking time out. And as for what's about to follow: “It's going to be a fun ride!” Hosted on Acast. See acast.com/privacy for more information.

Mit der Beschreibung der kleinen RNA-Moleküle haben die Preisträger Victor Ambros und Gary Ruvkun einen Prozess der Genregulation erklärt. MicroRNAs steuern die Produktion von Proteinen und sind damit entscheidend für die Entwicklung eines Organismus. Von Anneke Meyer

Krauter, Ralf www.deutschlandfunk.de, Forschung aktuell

Lange, Michael www.deutschlandfunk.de, Forschung aktuell

Two Americans have been awarded the Nobel prize for medicine. AP correspondent Jennifer King reports.

Jahrestag des Terrorangriffs der Hamas auf Israel, SPD-Generalsekretär Kevin Kühnert tritt aus gesundheitlichen Gründen zurück, Matthias Miersch wird neuer Generalsekretär der SPD, Medienbericht warnt vor Zahlungsunfähigkeit der Pflegeversicherung, Nobelpreis für Medizin geht an zwei US-Gen-Forscher für Entdeckung der "microRNA", Europäische Raumfahrtorganisation ESA schickt Sonde "Hera" zur Erforschung von Schutz vor Asteroiden-Einschlägen ins All, Das Wetter

Victor Ambros and Gary Ruvkun have discovered microRNA and its role in post-transcriptional gene regulation, revealing an entirely new dimension to gene regulation.

(1) Verrassingsaanval Hamas 7 oktober '23 toch niet zo'n verrassing (2) Lia van Bekhoven las memoires Boris Johnson (3) 1 op 7 studenten doet aan zelfverminking (4) Nobelprijs Geneeskunde naar ontdekking MicroRNA (5) Middagjournaal van Stella Bergsma

Early identification of diseases in animals is critical to the future of the food system, national security and our ability to care for our pets. One company is harnessing the power of biology to accelerate identification and joined us from the Agbioscience Podcast Corner at the Animal Health, Nutrition, Innovation and Technology Conference in Boston. Eve Hanks, founder and CEO of MI:RNA Diagnostics, joins us to talk their biomarker platform reliant on microRNA that has the potential to transform the future of animal health. Eve gets into how the platform works and success her team has experienced since spinning out of Scotland's Rural College. She also talks the importance of partnerships to drive innovation forward. With diseases like Avian Flu and African Swine Fever threatening the global food system, how can a tool like MI:RNA help? Eve talks combatting disease in animals and how an increased awareness of microRNA is driving interest in her team's work.

https://passionstruck.com/passion-struck-book/—Order a copy of my new book, "Passion Struck: Twelve Powerful Principles to Unlock Your Purpose and Ignite Your Most Intentional Life," today! The book was picked by the Next Big Idea Club as a must-read for 2024, the winner of the Business Business Minds Best Book 2024, and a finalist for the Eric Hoffer First Horizon Award for best debut novel.In this episode of Passion Struck, host John R. Miles interviews Dr. Michael Greger, a renowned physician and author who shares valuable insights on preventing diseases, improving health, and promoting longevity through lifestyle interventions. The episode covers a wide range of topics, including the impact of diet on heart disease, strategies for preserving bone health, tips for maintaining cognitive function and enhancing sexual health. Full show notes and resources can be found here:  https://passionstruck.com/dr-michael-greger-on-blueprint-for-healthy-aging/In this episode, you will learn:The importance of lifestyle interventions and promoting health and longevity based on his personal experience with his grandmother's recovery from heart disease.The impact of nutrition on preventing diseases like heart disease and cancer.Insights on the Mediterranean and Okinawan diets, emphasizing the benefits of whole plant foods for overall health.Strategies for preserving bone strength, cognitive health, and sexual function as part of an anti-aging approach.Xenohormesis and microRNA manipulation as potential mechanisms for improving health and longevity through plant-based diets and exercise.All things Dr. Michael Greger: https://nutritionfacts.org/SponsorsBrought to you by Indeed. Head to https://www.indeed.com/passionstruck, where you can receive a $75 credit to attract, interview, and hire in one place.Brought to you by Nom Nom: Go Right Now for 50% off your no-risk two week trial at https://trynom.com/passionstruck.Brought to you by Cozy Earth. Cozy Earth provided an exclusive offer for my listeners. 35% off site-wide when you use the code “PASSIONSTRUCK” at https://cozyearth.com/This episode is brought to you by BetterHelp. Give online therapy a try at https://www.betterhelp.com/PASSIONSTRUCK, and get on your way to being your best self.This episode is brought to you By Constant Contact:  Helping the Small Stand Tall. Just go to Constant Contact dot com right now. So get going, and start GROWING your business today with a free trial at Constant Contact dot com.--► For information about advertisers and promo codes, go to:https://passionstruck.com/deals/Catch More of Passion StruckWatch my interview with Dr. Lucia Aronica On The Impact Of Personalized Nutrition On EpigeneticsMy solo episode on how to heal from the consequences of abuseCan't miss my episode with Dr. Will Cole On How To Restore Your Gut-Feelings ConnectionListen to my interview with Dr. Kara Fitzgerald On How To Become A Younger You By Reversing Your Biological AgeMy solo episode on The Science Of Healthy HabitsCheck Out my episode with Dr. Mark Hyman On The Secrets To Living Young ForeverLike this show? Please leave us a review here-- even one sentence helps! Consider including your Twitter or Instagram handle so we can thank you personally!How to Connect with JohnConnect with John on Twitter at @John_RMiles and on Instagram at @john_R_Miles.Subscribe to our main YouTube Channel Here: https://www.youtube.com/c/JohnRMilesSubscribe to our YouTube Clips Channel: https://www.youtube.com/@passionstruckclips